Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Octant
AddedFeb 15, 2024
UpdatedJun 18, 2026
Octant

Octant

Octant, Inc.: A US-based biotech firm innovating in drug discovery with advanced genomic and computational tools.

HQ
Emeryville, CA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize drug discovery, Octant, Inc. is a biotechnology company based in the United States. The company aims to map a new universe of medicine by developing next-generation small molecule therapeutics. Utilizing synthetic biology, genome engineering, next-generation sequencing, and computational tools, Octant focuses on drugging the cellular mechanisms that cause disease. Their innovative approach moves beyond traditional methods by engineering biology to measure the activity of receptor pathways in human cells.

Octant has attracted notable investors and industry leaders, contributing to its rapid growth and recognition in the biotech sector. The company's key achievements include the development of multiplexed technologies that significantly enhance the precision and efficiency of drug discovery processes. By pioneering these advanced genomic and computational tools, Octant has made a substantial impact on the field of biotechnology, offering promising new avenues for treating complex diseases.

Octant - Similar Companies

Hexagon Bio logo

Hexagon Bio

hexagonbio.com

Septerna logo

Septerna

septerna.com

DeepBiome Therapeutics logo

DeepBiome Therapeutics

Antheia logo

Antheia

antheia.bio

Octamer logo

Octamer

Absci logo

Absci

absci.com

Owkin logo

Owkin

owkin.com

RootPath Genomics logo

RootPath Genomics

rootpath.com

10x Genomics logo

10x Genomics

10xgenomics.com

Singular Genomics logo

Singular Genomics

Cellanome logo

Cellanome

cellanome.com

Forcyte Biotechnologies logo

Forcyte Biotechnologies

forcytebio.com

BioSkryb Genomics logo

BioSkryb Genomics

bioskryb.com

Panorama Medicine logo

Panorama Medicine

BridGene Biosciences logo

BridGene Biosciences

Octant - Quick Facts

Who are Octant's competitors?

Companies similar to Octant include Hexagon Bio, Septerna, DeepBiome Therapeutics and Antheia.

When was Octant founded?

Octant was founded in 2017.

Where is Octant's headquarters located?

Octant's headquarters is located in Emeryville, CA, US.

When was Octant's last funding round?

Octant's most recent funding round was for $80M (USD) in April 2022.

How much has Octant raised to-date?

As of Apr 28, 2022, Octant has raised a total of $115M (USD).

How many employees does Octant have?

Octant has 85 employees as of Feb 4, 2024.

Octant - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software